Unlock this StockReport nowClick to Unlock

Bayer AG Share Price

BAYN €59.65 0.7  1.2%

Relative Strength (%)
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
Margin of Safety (beta)
Screens Passed 1 / 2
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2013 2014 2015 2016 2017 2018 TTM 2019E 2020E CAGR / Avg
Revenue €m
Operating Profit €m
Net Profit €m
EPS Reported
EPS Normalised
EPS Growth %
PE Ratio x
Operating Margin %
Op. Cashflow ps
Capex ps
Free Cashflow ps
Last ex-div: 29th Apr, paid: 2nd May more... Dividends
Dividend ps
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc €m
Working Capital €m
Net Fixed Assets €m
Net Debt €m
Book Value €m
Average Shares m
Book Value ps +14.9%

FINANCIAL BRIEF: For the three months ended 31 March 2019, Bayer AG revenues increased 42% to EUR13.02B. Net income before extraordinary items decreased 36% to EUR1.24B. Revenues reflect CropScience segment increase from EUR2.86B to EUR6.44B, Pharmaceuticals & Biological Products segment increase of 7% to EUR4.35B, North America segment increase of 97% to EUR5.21B, Europe Middle East and Africa segment increase of 14% to EUR4.05B. more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score
Other Ratios
Leverage (ttm) Total -Intang +Pension
Gross Gearing %
Net Gearing %
Cash / Assets %
Recent History
Latest interim period (ended 31st Mar '19) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2019
31st Dec 2020

Price Target: €76.5
(+29.91% above Price)
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: +11.2% (€) (€) (€) (€) (€) (€)
Consensus Estimate
1m Change
3m Change
27 brokers Broker Consensus Trend
Broker Recommendations for Bayer AG
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 0 2 13 8 5

Named Brokers and Analysts
Bank of America Merrill Lynch Sachin Jain , Deutsche Bank Falko Friedrichs , Jefferies , HSBC Stephen McGarry , Credit Suisse - North America Jo Walton , Morgan Stanley , Citi Peter Verdult , Commerzbank Corporates & Markets Daniel Wendorff , BERNSTEIN Jeremy Redenius , Goldman Sachs Research Keyur Parekh , UBS Equities Alexandra Hauber , Warburg Research GmbH Ulrich Huwald , Banco Santander Alejandro Conde , Natixis , Analisis Banco Sabadell Oscar Rodriguez , Exane BNP Paribas , Societe Generale Florent Cespedes , ESN/ equinet Bank (Germany) , Pareto Securities AS Dennis Berzhanin , JPMorgan Richard Vosser , Berenberg Sebastian Bray , DZ Bank Peter Spengler , Nord/LB Thorsten Strauss , Bankhaus Lampe Volker Braun , Kepler Cheuvreux David Evans , Barclays Emmanuel Papadakis , Bryan Garnier Jean-Jacques Le Fur , MainFirst Bank AG Michael Leacock , Morningstar, Inc. Damien Conover , VRS (Valuation & Research Specialists) , Day by Day Valérie GASTALDY , Landesbank Baden-Wuerttemberg Ulle Woerner , Liberum , Alphavalue Martin Schnee , Baader Helvea Equity Research Markus Mayer , Invest Securities ,

Profile Summary

Bayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science and Animal Health. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and ophthalmology, as well as radiopharmacology and others. The Consumer Health segment develops, produces and markets nonprescription over-the-counter products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories, among others. The Crop Science segment researches, develops and markets crop protection solutions and seeds, and includes the subsidiary Monsanto. The Animal Health segment is engaged in the development, production and marketing of prescription and nonprescription veterinary products.

Directors: Werner Wenning (CSU) 72, Werner Baumann (CMG) 56, Oliver Zuehlke (VSU) 50, Wolfgang Nickl (CFO) 49, Hartmut Klusik (CTO) 62, Liam Condon (MGB) 51, Kemal Malik (MGB) 56, Stefan Oelrich (MGB) 50, Heiko Schipper (MGB) 49, Paul Achleitner (IND) 62, Simone Bagel-Trah (IND) 50, Norbert Bischofberger (IND) 63, Thomas Ebeling (IND) 60, Thomas Elsner (IND) 60,

No. of Employees: 116,428 No. of Shareholders: n/a

Last Annual December 31st, 2018
Last Interim March 31st, 2019
Public Since November 28, 1997
Shares in Issue 932,551,964
Free Float 932.5m (100.0%)
Sector Healthcare
Industry Pharmaceuticals
Index FTSE Global 100,
Exchange Frankfurt Stock Exchange (Dual Listing)
Eligible for an ISA? a SIPP?

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2019.

Should you buy BAYN

Access BAYN Analytics Now!

Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis